New Infusion Treatment for Thyroid Eye Disease

Lumvoa (veligrotug-vvze; pronounced lum-VOE-ah) is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor — a humanized IgG1κ monoclonal antibody given by intravenous infusion. It is not a steroid course, not orbital surgery, and not a cure for Graves’ disease or TED. The US indication covers TED whether the disease is called active or chronic and regardless of how long TED has been present.

The FDA approved BLA 761530 on 26 June 2026 (Novel Drug Approvals for 2026, row 23). The application received Priority Review and had previously received Breakthrough Therapy Designation. The licence holder is Viridian Therapeutics, Inc. (Waltham, MA; U.S. License No. 2377).

The labelled regimen is a finite 12-week course: 10 mg/kg every three weeks for a total of five infusions. That is shorter than some other IGF-1R TED regimens patients may have heard about — compare labels with the clinic; do not self-substitute one product for another.

Where this is taking place

Commercial labelled supply today: United States — FDA full approval for TED regardless of activity or duration. Infusions are clinic-based (diluted into 0.9% sodium chloride; first infusion over 45 minutes; later infusions may run over a minimum of 30 minutes if the first was well tolerated). This is not a home injection and not an IV push or bolus.

Outside the United States: As of this draft, no Health Canada Notice of Compliance, European Commission marketing authorisation, MHRA licence, PMDA/MHLW licence, TGA ARTG listing, Swissmedic authorisation, or NMPA decision has been confirmed from primary regulator pages for this article. Company materials have described a Marketing Authorisation Application to the EMA (submitted early 2026 / under review in secondary digests). MAA under review ≠ EC licence. A US carton is not an EU, UK, Canadian, Japanese, Australian, Swiss, or Chinese label.

THRIVE (NCT05176639 / Study 1) — Phase 3, active TED, sponsor Viridian Therapeutics, Inc. CT.gov status: COMPLETED (start 16 Nov 2022; primary completion 15 Jul 2024; completion 27 Mar 2025). Actual enrolment 113 (75 Lumvoa / 38 placebo). Countries with listed sites include the United States, Australia, France, Germany, Poland, Spain, and the United Kingdom. No Canadian sites on the CT.gov location list retrieved for this draft. Not an enrolment path for newly labelled commercial use.

THRIVE-2 (NCT06021054 / Study 2) — Phase 3, chronic TED, sponsor Viridian. CT.gov status: COMPLETED (start Nov 2023; primary completion 4 Nov 2024; completion 25 Jul 2025). Actual enrolment 188 (125 Lumvoa / 63 placebo). Countries with listed sites include the United States, Australia, France, Germany, Hungary, Poland, Spain, Turkey (Türkiye), and the United Kingdom. No Canadian sites on the CT.gov list retrieved here. Not an enrolment path.

The practical door in the US is an oculoplastic, orbital, neuro-ophthalmology, or TED-experienced endocrinology clinic that can order the infusions, check hearing and glucose, and manage infusion reactions — not a mail-order vial.

Approval matrix

Access by country

• United States: Ask an oculoplastic / orbital / neuro-ophthalmology / TED clinic about FDA-labelled Lumvoa. Labelled 26 June 2026 for thyroid eye disease regardless of activity or duration. Dose: 10 mg/kg IV every three weeks for five infusions (about 12 weeks). First infusion 45 minutes; later infusions ≥30 minutes if tolerated. Prior authorisation and specialty / buy-and-bill logistics still apply. No list price or copay dollars in this article. Viridian patient-support programme named in the company approval press: ViridianCares™ — 866-VCARES1 (866-822-7371) for access-liaison / benefit-verification framing (company press — not a formulary guarantee). Adverse reactions / medical information on the USPI: Viridian Therapeutics 1-866-321-VRDN (1-866-321-8736) or FDA MedWatch 1-800-FDA-1088. Prescribing Information host: viridiantherapeutics.com/lumvoa-prescribing-information. This is US commercial labelled supply, not Special Access and not a DIY import.

• Canada: Authorisation not confirmed. Neither THRIVE nor THRIVE-2 lists Canadian sites on the CT.gov records retrieved here. Do not assume SAP, named-patient, or cross-border mail-order is available or appropriate. Ask the TED / oculoplastics clinic what legal paths exist in Canada when a Canadian label does not yet exist.

• European Union: EC marketing authorisation not confirmed. Company materials describe an EMA MAA as submitted / under review. That is a filing, not a licence. Member-state reimbursement questions do not arise until there is an MA — and even then, authorised ≠ funded.

• United Kingdom: MHRA authorisation not confirmed. UK trial sites (for example Moorfields, Western Eye / Imperial, Guy’s and St Thomas’s, Newcastle, Southampton on THRIVE-2) are not a marketing authorisation.

• Australia / other countries with trial sites: Trial participation is not a commercial label. Regulator authorisation not confirmed in this draft.

• If your regulator has not authorised it: do not import on your own.

Who is eligible (from the US label)

This is a thyroid eye disease conversation. The US line does not require the disease to be “active only” or “within X months.”

United States (USPI / DailyMed, revised 06/2026):

• Indication: Treatment of thyroid eye disease regardless of thyroid eye disease activity or duration.
• Dose: 10 mg/kg by IV infusion every three weeks for a total of 5 infusions.
• Administer diluted in 250 mL 0.9% Sodium Chloride; not as IV push or bolus; do not co-infuse other agents.
• First infusion over 45 minutes; subsequent infusions over a minimum of 30 minutes if the first was well tolerated (otherwise keep 45 minutes).
• Contraindications: None.
• Pediatrics: Safety and effectiveness not established.
• Geriatrics: Of 301 patients in Studies 1 and 2, 12% were ≥65 years; no overall differences in safety or effectiveness observed versus younger adults in that set.
• Pregnancy / reproductive potential: May cause fetal harm (IGF-1R signalling matters for embryonic / placental development). Do not use during pregnancy. Effective contraception before starting, during treatment, and for 6 months after the last dose. Pregnancy test before starting when applicable. Insufficient human pregnancy data; animal reproductive studies not conducted with Lumvoa.
• Lactation: No information on presence in human milk.
• Hearing was screened carefully in the trials (abnormal baseline audiometry / significant ear pathology excluded). The label still requires hearing assessment before, during, and after treatment because impairment may be permanent.
• Patients with biopsy-proven or clinical IBD were excluded from the pivotal trials; the label still tells clinicians to monitor for IBD even without a prior diagnosis and to discontinue if IBD is suspected.

Not labelled on sources confirmed for this draft:

• EU, UK, Canadian, Japanese, Australian, Swiss, or Chinese marketing authorisations (not confirmed here).
• A home subcutaneous TED product (Viridian’s subcutaneous TED candidate is a separate development programme — not this label).
• Use as a substitute for urgent orbital decompression when the clinic says surgery cannot wait (trial entry required that immediate surgery was not needed).

What the pivotal studies showed (US label Section 14)

Efficacy below is from the US Prescribing Information for Studies 1 and 2. Use the label of the country that will prescribe — outside the US there is no confirmed label in this draft.

Both studies: randomised 2:1, double-masked, placebo-controlled; 10 mg/kg or placebo IV every 3 weeks × 5 infusions. Primary timepoint Week 15. Proptosis responder = ≥2 mm reduction in the study eye without ≥2 mm worsening in the fellow eye (exophthalmometer; MRI/CT showed similar patterns).

Proptosis improvement was seen as early as Week 3 in both studies (label figures). Among Week-15 proptosis responders, 71% (Study 1) and 57% (Study 2) maintained proptosis response at Week 52. Among those with diplopia resolution at Week 15, 50% (Study 1) and 80% (Study 2) maintained resolution at Week 52.

Trial status honesty: Both pivotal trials are COMPLETED. They are evidence for the US label, not a door to start the drug outside commercial US distribution.

How it is given (on-label)

Weight-based vial count: each vial holds 500 mg; the clinic calculates milligrams from weight (kg × 10) and withdraws the matching volume.

Safety (what the label puts first)

Infusion reactions (~9%): May occur during or soon after an infusion — transient blood-pressure rise, fever, chills, headache, fatigue. Usually mild or moderate; managed with corticosteroids, antihistamines, antipyretics, slower rate, and/or premedication.

Inflammatory bowel disease: IGF-1R inhibitors have been linked to IBD flares, including in people without a prior IBD diagnosis. Seek care for diarrhea (with or without blood), rectal bleeding, abdominal pain/cramping, urgency, tenesmus, or incontinence. Discontinue if IBD is suspected.

Hyperglycemia: Label Warnings narrative: 12% of patients (about half with preexisting diabetes or impaired glucose tolerance) had hyperglycemia. Adverse-reaction table: hyperglycemia 13% vs 5% placebo. Check glucose before infusions and while on treatment; keep diabetes under control before and during; continue monitoring after treatment if hyperglycemia occurred on drug.

Hearing impairment including hearing loss (may be permanent): Assess hearing before, during, and after. Adverse-reaction table: hearing impairment 15% vs 6% placebo (includes tinnitus, hypoacusis, deafness, autophony). Ear discomfort 10% vs 3%. Contact the clinic for any hearing change.

Most common adverse reactions (≥5% and greater than placebo) — pooled Studies 1 and 2 (Lumvoa N=200 vs placebo N=101): muscle spasms 40% vs 7%; headache 17% vs 14%; hearing impairment 15% vs 6%; hyperglycemia 13% vs 5%; fatigue 13% vs 11%; diarrhea 11% vs 7%; ear discomfort 10% vs 3%; infusion-related reaction 9% vs 2%; nausea 8% vs 6%; nasopharyngitis 7% vs 1%; blood CPK increased 6% vs 1%; dry skin 6% vs 2%; hypertension 6% vs 5%.

Menstrual disorders (amenorrhea, irregular menses, dysmenorrhea, delayed menses, intermenstrual bleeding, menstrual disorder): about 29% (24/82) of menstruating women on Lumvoa vs 6% (2/33) on placebo.

Follow-up period notes on the label include alopecia and onychoclasis (5%); immune thrombocytopenia was reported in one patient.

Contraindications: none.

Immunogenicity: Treatment-emergent anti-veligrotug antibodies in 20% (58/290) of evaluable patients; no apparent overall link to PK, safety, or effectiveness in the label’s summary.

How to talk to a doctor

Bring the NCT numbers, the BLA number, and the US Prescribing Information if you are in a US clinic. Outside the US, bring honesty that a local label may not exist yet.

1. "I have thyroid eye disease. The US label covers TED regardless of activity or duration. Is Lumvoa (veligrotug-vvze) labelled for me in this country?"
2. "The labelled course is five IV infusions over 12 weeks at 10 mg/kg every three weeks. Who at this centre orders and gives TED biologic infusions?"
3. "Please plan hearing checks before, during, and after — the label says impairment can be permanent."
4. "Please check my blood glucose and diabetes plan — hyperglycemia happened in about 12–13% in the trials."
5. "I will watch for infusion reactions and for IBD-type bowel symptoms, even if I have never had IBD."
6. "If I can become pregnant: contraception during treatment and for 6 months after the last dose — and a pregnancy test before starting."
7. "Is prior authorisation started? Who coordinates the NDC 85166-001-01 vial and infusion-suite scheduling?"
8. "EU, Canadian, and other ex-US authorisations are not confirmed on the sources we are using — I will not import a foreign carton."
9. "If we are outside the US, what legal options exist while an EMA MAA is only described as under review — local special-access rules, or referral — without DIY import?"

Research and regulatory team (from sources only — no invented contacts)

• Viridian Therapeutics, Inc., 221 Crescent Street, Suite 103A, Waltham, MA 02453 — BLA 761530 licence holder; U.S. License No. 2377; THRIVE / THRIVE-2 sponsor; manufacturer named on the USPI.
• Steve Mahoney — President and CEO, Viridian; quoted on the 26 June 2026 company approval press.
• Michael T. Yen, M.D. — Professor of Oculoplastic Surgery and Ophthalmology, Baylor College of Medicine; THRIVE investigator quoted on the company approval press; first author of the Ophthalmology THRIVE paper (Yen MT, Cockerham K, Saeed P, et al.; THRIVE Study Group).
• Kimberly Cockerham, M.D. — THRIVE Ophthalmology co-author; Cockerham Eye Consultants listed on THRIVE-2 CT.gov.
• Amy Patel Jain, M.D. — named on THRIVE-2 abstract / CT.gov facility listings (Newport Beach, US).
• Additional THRIVE Ophthalmology byline names (source paper): Peerooz Saeed; Steven Leibowitz; Raghu C. Mudumbai; Michael P. Schittkowski; Vickie Lee; Jody Abrams; Roger E. Turbin; Julián Bermúdez Pío-Rendón; Eckart Bertelmann; Edwina Eade; Navdeep Nijhawan; Marta Pérez-López; Marco Sales-Sanz; Sandy Zhang-Nunes; Andrea L. Kossler; Ashley Pajak; Abhijit Narvekar; Radhika Tripuraneni; Antonio Manuel Garrido-Hermosilla — on behalf of the THRIVE Study Group.
• Christine Gustafson — Founder / CEO / Executive Director, TED Community Organization; quoted on the company approval press (patient-community voice, not a prescribing contact).
• ViridianCares™ — company patient-support programme named in the 26 June 2026 press: 866-VCARES1 (866-822-7371).
• USPI adverse-reaction contact: 1-866-321-VRDN (1-866-321-8736); MedWatch 1-800-FDA-1088.
• CT.gov overall officials / central contacts: not named on the NCT05176639 or NCT06021054 API records retrieved for this draft.

Bottom line

Lumvoa (veligrotug-vvze) is an FDA-approved IGF-1R monoclonal antibody for thyroid eye disease regardless of activity or duration, labelled 26 June 2026 (BLA 761530). The course is five IV infusions over 12 weeks (10 mg/kg every three weeks). THRIVE (active) and THRIVE-2 (chronic) both met Week-15 proptosis endpoints, with diplopia response and resolution also better than placebo on the US label. Watch hearing, glucose, infusion reactions, and IBD symptoms. US labelled; other regulators not confirmed. An EMA MAA under review is not a European licence. The door is a TED-capable infusion clinic writing the US label. This is not home self-administration.

---

Primary sources

1. FDA Novel Drug Approvals for 2026 — Lumvoa / veligrotug-vvze, approval date 6/26/2026, row 23 — https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
2. Lumvoa (veligrotug-vvze) Prescribing Information, revised 06/2026, Viridian Therapeutics (Final USPI PDF) — https://www.viridiantherapeutics.com/wp-content/uploads/2026/06/Lumvoa-veligrotug-Final-USPI_26Jun2026.pdf
3. FDA label PDF, BLA 761530 — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761530Orig1s000lbl.pdf
4. DailyMed LUMVOA (veligrotug-vvze), setid 11bc286a-5411-45af-af3f-69ad38efb610 — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=11bc286a-5411-45af-af3f-69ad38efb610&type=display
5. Viridian Therapeutics press — FDA Approval and Launch of Lumvoa (veligrotug-vvze), 26 June 2026 — https://investors.viridiantherapeutics.com/news/news-details/2026/Viridian-Therapeutics-Announces-U-S--FDA-Approval-and-Launch-of-Lumvoa-veligrotug-vvze-for-the-Treatment-of-Thyroid-Eye-Disease/default.aspx
6. ClinicalTrials.gov NCT05176639 — THRIVE (active TED) — https://clinicaltrials.gov/study/NCT05176639
7. ClinicalTrials.gov NCT06021054 — THRIVE-2 (chronic TED) — https://clinicaltrials.gov/study/NCT06021054
8. Yen MT, Cockerham K, Saeed P, et al.; THRIVE Study Group. THRIVE: a phase 3, randomized, double-masked, placebo-controlled study of veligrotug for active thyroid eye disease. Ophthalmology. 2026. doi:10.1016/j.ophtha.2026.04.022